Stable and safe vascular access has become essential to modern medical practice. Noncuffed percutaneously inserted central venous catheters (CVCs) are widely used, with over 7 million sold each year in the United States alone (88), and are used for administration of intravenous fluids, blood products, medications, hemodynamic monitoring, parenteral nutrition, and access for blood specimens. The most common life-threatening complication of central venous access is bloodstream infection, caused by colonization of the implanted catheter or contamination of the catheter hub or infusate administered through the device (88,91). CVCs are now the most frequent source of nosocomial bloodstream infection (13,87,88,94,141), and it has been estimated that 250,000– 500,000 episodes occur in the United States annually (13,59,87,94,110,141), with an estimated 10% mortality (88,135,168) and marginal cost to the health care system of $25,000 per episode (9,59,110,135,168).
Measures to prevent CVC-related bloodstream infection are most likely to be effective if they are guided by a full understanding of the pathogenesis and epidemiology of these infections. We report a critical analysis of reported risk factors for the development of CVC-related bloodstream infection deriving from percutaneously inserted, noncuffed CVCs.
English-language prospective studies in adults were identified by a MEDLINE (National Library of Medicine, Bethesda, MD) search (keywords:risk factors, intravascular devices, central venous catheter and infection) and by reviewing the citations of published reviews of intravascular device-related infection (1,31,40,41,47,54,77,88,94,110–112,116,131,141,142,144). The following criteria were required for a study to be included in this analysis: 1) the exact type of device was described; 2) all devices were prospectively evaluated for risk of device-related bloodstream infection by removal and culture of the device for evidence of colonization by the same organism (genus and species) isolated from blood cultures, with no extravascular source of bloodstream infection identified; and 3) the relative risk of device-related bloodstream infection was evaluated by a multivariable regression model or a potential control measure was assessed in a prospective randomized trial.
Overall, several thousand studies were ultimately reviewed. Unfortunately, many were very small and had limited statistical power, addressed only a limited number of potential risk factors, or did not quantify the magnitude of risk for individual risk factors. However, 96 studies were identified that provided usable data (167,170–176,183): prospective cohort studies of risk factors that used multivariable techniques of statistical risk factor analysis (170–172,183) and prospective randomized trials of a control measure aimed at reducing the risk of catheterrelated bloodstream infection (4,5,10,16,19,24–27,32,35,44–46,48,49,51,58,61,67,69,71,72,76,79,81,83,89,90,92,93,96,97,99–102,104,107,115,117,120,125,132,137–140,143,151,159–161,163,167,169,173–176,178,179,184).
Tables 1, 2, and 3 summarize the findings of this review. Numerous risk factors were found to be associated with a significantly increased risk of CVCrelated bloodstream infection in at least 1 study; a small number were found to be consistently associated with increased risk in the majority of studies that examined the factor: insertion with less than maximal sterile barriers (120), placement of a CVC in the internal jugular or femoral vein rather than subclavian vein (53,58,113,115,134,152), placement in an old site by guidewire exchange (11,26,45,72,117,129,133,137,157,169,172), heavy cutaneous colonization of the insertion site (8,27,49,85,121), contamination of the catheter hub (159), and duration of CVC placement greater than 7 days (43,121,152).
The largest and best-controlled randomized trials of control measures addressed the use of maximal sterile barriers at the time of CVC insertion (140), the use of chlorhexidine rather than povidone-iodine for cutaneous site disinfection (99,120,163), the utility of topical anti-infective creams or ointments on the insertion site (63,76), the impact of transparent polyurethane film dressings as contrasted with standard sterile gauze (4,27,44,83,125,138,139,184), the use of multi-lumen rather than single-lumen CVCs (25,46,52,75,107,137), and the efficacy of novel technology, such as antiseptic-impregnated site dressings (51,97), attachable silver-impregnated cuffs (48,90,126), or especially, anti-infective coatings (24,35,58,71,79,100,132,143,173). The vast majority of studies was restricted to percutaneously inserted noncuffed single- or more commonly multi-lumen catheters (81 studies) (3–5,7,8,10,12,16,19,21,24–27,33–35,39,43–46,48–53,57,58,61,64–67,69,71,72,75,79–81,84,85,89,90,92,93,95–97,99–107,115,117,119–121,124–126,132,134,137–140,143,151,152,157,159,163,166,167,169–175,178,179,183,184). Far fewer studies addressed risk factors for catheter-related bloodstream infection with noncuffed CVCs used for hemodialysis (2,32,105,129,161,176) or noncuffed pulmonary artery Swan-Ganz catheters (18,33,76,101,113,123,150,160).
This review identified a number of important risk factors associated with a significantly increased risk of catheter-related bloodstream infection with noncuffed percutaneously inserted CVCs, all of which are potentially amenable to control by preventive strategies (Table 4).
Training and experience of the inserter
CVCs are associated with significant potential for life-threatening iatrogenic complications besides catheter-related bloodstream infection, including pneumothorax, vascular injury, arrhythmias and thromboembolism (136). Armstrong et al (7) identified inserter experience as an important risk factor for CVC-related bloodstream infection in a prospective study of 169 catheters. Moreover, a recent survey of United States academic medical centers has shown that up to one-half of clinicians who use pulmonary artery catheters have major gaps in their understanding of when to use the catheter and how to interpret the data derived from it (68). Only in recent years are United States institutions requiring formal training of house officers in the techniques of vascular access (6). Studies (38,130) have shown that intensified training and educational programs can greatly reduce the baseline risk of CVC-related bloodstream infection in a center.
Clinicians using CVCs must understand clearly their indications and potential for complications, and should be formally certified in the insertion, maintenance, and use of these catheters. Inexperienced users should be personally supervised and trained by an experienced physician (Table 5) (128).
Sterile barrier precautions
Mermel et al (113) found in a prospective study of 302 pulmonary-artery catheters that failure to use maximal sterile barriers at the time of catheter insertion increased the risk of catheter-related infection more than twofold (relative risk [RR] 2.1; 95% confidence interval [CI] 1.1– 5.2). Whereas the issue has not been studied extensively, in 1 well-controlled randomized trial (140) it was found that the use of maximal sterile barriers when inserting a CVC in a patient with cancer greatly reduced the risk of CVC-related bloodstream infection (RR 0.20; 95% CI 0.02– 1.2). It seems clear that physicians inserting a CVC should wear a long-sleeved sterile surgical gown and sterile gloves and, to be in compliance with universal precautions, a mask and eye cover; the potential insertion site should be draped with a large sterile sheet (see Table 5) (128).
Site of insertion
At least 6 studies, including 1 randomized clinical trial, have found that percutaneous insertion of a CVC in an internal jugular or femoral vein is associated with a substantially higher risk of catheterrelated bloodstream infection than insertion in a subclavian vein (RR 1–3.3) (53,58,113,115,134,152). Whereas placement in an internal jugular or femoral vein is associated with less risk of pneumothorax and permits control of local hemorrhage by the application of pressure, the risk of mechanical complications with central venous cannulation, such as pneumothorax or hemorrhage, has greatly declined in recent years (118), reflecting better training in the techniques of percutaneous catheter insertion and a much greater experience. It should be possible to place a CVC percutaneously in the subclavian vein with a very low risk of barotrauma, in the range of 1% or less.
These data indicate that training programs should strive to encourage use of the subclavian vein as the preferred site of access for CVCs (other than catheters needed for long-term hemodialysis [17,21]), and should assure that all house officers and fellows are trained in establishing central access in the subclavian vein (see Table 5) (128).
Tunneling a CVC appears to reduce the risk of catheter-related bloodstream infection, both with catheters placed in the internal jugular or femoral veins (148,174,175), and might be considered if circumstances favor cannulation of an internal jugular or femoral vein rather than a subclavian vein (for example, severe coagulopathy or a hemodialysis catheter). Finally, use of a catheter with an anti-infective coating can also reduce the otherwise overall risk of infection in this circumstance (35,100,143).
Catheter exchange over a guidewire
The Seldinger technique for catheter insertion has been a major advance, permitting the great central veins to be cannulated with considerably less risk of pneumothorax and vascular injury. To avoid iatrogenic mechanical complications associated with percutaneous insertion of another CVC, new catheters are commonly inserted over a guidewire in the site of an old catheter. Numerous studies have examined the impact of this practice on the risk of infection (11,26,45,72,117,129,133,137,157,169,172); however, most did not utilize multivariable techniques. Eight randomized trials addressing this issue have had conflicting results (11,26,45,72,117,137,160,169). The best prospective randomized trial (26), which included pulmonary-artery catheters, found a nearly twofold increased risk of catheter-related bloodstream infection with CVCs replaced on a periodic basis in old sites over a guidewire; 75% of all catheter-related bloodstream infections in the study population occurred within 72 hours of catheter exchange over a guidewire. Authors (28) of a metananalysis of the effect of guidewire exchange and new site replacement strategies for central venous catheters in critically ill patients found a trend toward a higher rate of catheter-related bloodstream infection with guidewire exchange (RR 1.72; 95% CI 0.12–1.91).
When a CVC must be replaced because of suspicion of infection (for example, unexplained fever), or the catheter has malfunctioned, it is reasonable to replace a catheter in the same site over a guidewire if the patient has limited sites for new access or would be a high risk for percutaneous central venous cannulation in a new site (for example, coagulopathy or morbid obesity). However, it is imperative that the same meticulous aseptic technique and use of full sterile barriers that are mandatory during the insertion of any new CVC be employed. After vigorously cleansing the site with the antiseptic solution, inserting the guidewire, removing the old catheter, and cleansing the site once more with the antiseptic solution, the operator should reglove and ideally redrape the site, as the original gloves and drapes are likely to have become contaminated from manipulation of the old catheter (110,128).
In general, if the old insertion site is inflamed, especially if it is purulent, or the patient shows signs of sepsis that might be originating from the catheter or the patient has cryptogenic bacteremia or candidemia, it is strongly recommended that a new catheter not be inserted over a guidewire into an old, potentially infected site. When a catheter is inserted in an old site over a guidewire, it is essential to culture the old catheter routinely, and, if the patient is febrile or shows other soft signs of sepsis, to obtain blood cultures. If these cultures demonstrate that the old catheter was infected, the new catheter placed in an old site should be removed immediately to prevent progression of catheter-related bloodstream infection or perpetuation of ongoing bloodstream infection, as a new catheter has been inserted into an infected tract; need for continued access would mandate placement of a new catheter in a new site. If culture of the old catheter shows that it is not colonized, it has been possible to preserve access and exclude it as the cause of fever and sepsis without subjecting the patient to the hazards associated with percutaneous insertion of a new catheter (see Table 5) (128).
The use of novel technologies can further reduce the increased risk of catheter-related bloodstream infection with necessary guidewire catheter exchanges, particularly the use of catheters with an anti-infective coating (35,58,71,79,100,143,173,176). It is noteworthy that the application of silver-impregnated cuffs, which significantly reduced the risk of catheter-related bloodstream infection with first catheters in a site, was not effective for reducing risk with second catheters placed in old sites over a guidewire (90).
Heavy colonization of the insertion site
Colonization of the insertion site will be greatly influenced by the choice of the site. In a prospective study (86), it was found that the density of the transient cutaneous microflora was highest at the base of the neck, the site of insertion of an internal jugular vein catheter, as contrasted with over the upper chest, the site of insertion of a subclavian vein catheter.
Given the powerful evidence for the importance of cutaneous microorganisms and particularly the density of the microflora at the potential insertion site in the pathogenesis of CVC-related infection, measures to reduce cutaneous colonization of the insertion site are of the highest priority, particularly the choice of the chemical antiseptic used for disinfecting the site. In the United States, iodine-based disinfectants, particularly iodophors such as 10% povidone-iodine, are used most widely. Chlorhexidine, a biguanide with potent and broad-spectrum activity, exhibits prolonged antimicrobial activity on the skin surface after a single application, in contrast with alcohol or iodine-based antiseptics. To date, 7 prospective randomized clinical trials (51,67,92,99,108,120,163) have examined the relative efficacy of 10% povidone-iodine and chlorhexidine antisepsis for vascular access. The largest, a prospective randomized trial (92) with 850 CVCs and arterial catheters used in patients in an intensive care unit, showed that 2% chlorhexidine was superior to 10% povidone-iodine or 70% alcohol for prevention of CVC-related bloodstream infection (RR 0.36; 95% CI 0.14–0.95). In 6 of the 7 trials to date, chlorhexidine was superior to povidone-iodine for preventing catheter colonization, and in 2, CVC-related sepsis was reduced significantly. These studies in aggregate indicate that a 0.5%–2% chlorhexidine-alcohol tincture or a 1%–2% aqueous solution is more effective than iodophors or 70% alcohol for prevention of CVC-related colonization and bloodstream infection.
Disinfection of skin should be done with an appropriate antiseptic before catheter insertion and at the time of dressing changes. A 2% chlorhexidine-based preparation is preferred. Alternatively, tincture of iodine, an iodophor, or 79% alcohol could be used. Allow the antiseptic to remain on the insertion site and to dry before inserting the catheter. Allow povidone-iodine to remain on the skin for at least 2 minutes, or longer if it is not yet dry before inserting the catheter (see Table 5) (128).
“Defatting” the insertion site
Many parenteral nutrition support programs still use acetone to “defat” the skin as part of the regimen for disinfecting the site before insertion of the CVC and in follow-up care of the site, usually every other day. Defatting is widely practiced and included in many published protocols for the care of CVCs but appears to have no scientific rationale. Investigation suggests to the contrary that the natural skin lipids, especially the free fatty acids, contribute substantially to intrinsic antimicrobial properties of normal skin, and application of organic solvents promote and prolong colonization by pathogenic microorganisms (73). In the single prospective randomized clinical trial (93) of this issue, defatting with acetone before CVC insertion and as part of every-other-day site care showed no benefit whatsoever for prevention of catheter colonization or CVC-related bloodstream infection (RR 1.0; 95% CI 0.18–5.5); however, discomfort at the insertion site was twice as frequent with acetone as without (80% versus 35%, p < 0.001). These data suggest that defatting should not be employed routinely as part of the regimen for cutaneous disinfection of insertion sites for CVCs or other percutaneous intravascular devices (see Table 5) (128).
Topical anti-infective creams or ointments
In theory, application of a topical antimicrobial agent to the catheter insertion site should confer some protection against microbial invasion. Two studies have examined the effectiveness of applying a topical antiseptic (povidone-iodine ointment) daily to CVC insertion sites. The first, a large prospective randomized trial with all types of noncuffed CVCs used in a surgical intensive care unit, showed no benefit whatsoever (104). In contrast, Levin at al (76) found that application of topical 10% povidoneiodine ointment to the insertion site of noncuffed subclavian CVCs used for hemodialysis at the time of insertion and at all subsequent dressing changes, 3 times weekly, was associated with a fourfold reduction in the incidence of staphylococcal catheterrelated bacteremia (RR 0.09; 95% CI 0.01–0.54).
More recently, randomized trials have shown that the periodic application of topical antibacterial creams or ointments, such as mupirocin, can significantly reduce the risk of CVC-related bloodstream infection (63,161). However, studies have also shown that routine use of mupirocin on CVC sites greatly increases mupirocin resistance among staphylococci recovered from infected catheters in the center (185). The ecologic impact of routine use of topical antibacterials on CVC insertion sites bears critical scrutiny because of the high likelihood of promoting resistance (30,145,146,185). Moreover, polyurethane catheters may be damaged by exposure to these agents (149,153).
These data suggest that topical antibiotic ointments or creams should not be applied routinely on CVC insertion sites. Povidone-iodine ointment may be applied at the insertion site of a hemodialysis catheter after catheter insertion and at the end of each dialysis session as long as there is no interaction with the material of the hemodialysis catheter, per manufacturer’s recommendation (see Table 5) (128).
The importance of the cutaneous microflora in the pathogenesis of CVC-related infection suggests that the dressing applied to the insertion site could have considerable influence on the incidence of catheter-related infection. In recent years, transparent polyurethane film dressings have become available. They secure the device more reliably, permit continuous inspection of the site, and are generally more comfortable than gauze and tape; moreover, they permit patients to bathe and shower without saturating the dressing. Studies of polyurethane dressings on short-term noncuffed CVCs have yielded conflicting results (4,27,44,83,96,102,125,138,139,184); however, a metananalysis (65) of the largest and most rigorously controlled randomized trials has shown that these dressings do not materially increase the risk of CVC-related bloodstream infection (RR 0.99; 95% CI 0.90– 1.09). If the patient is diaphoretic, or if the site is oozing or bleeding, a gauze dressing is preferable to a transparent semipermeable dressing (128).
Manipulations of the system
Contamination of infusate, stopcocks or catheter hubs, the cause of many CVC-related bloodstream infections, has been the cause of most outbreaks of infusion-related bacteremia or candidemia (36,70,82,98). In general, running infusions should be manipulated as little as possible, and persons handling or entering the sytem should first wash their hands or don clean gloves. Efforts should be made to limit entry into the monitoring circuit for the purpose of drawing blood or other tests (128). The number of stopcocks in the system should also be kept to a minimum. It is unknown whether wiping a stopcock that has been opened with an anti-infective agent is of value.
New technology for prevention
The development and application of new technology holds the greatest promise for a quantum reduction in the incidence of nosocomial infections in general, and bloodstream infections deriving from devices used for intravascular access in particular (141). Innovations in the design or construction of the device that deny access of microorganisms to the system, or prevent organisms that gain access from proliferating into high concentrations or colonizing the surface of the implanted device, can obviate poor antiseptic technique or heavy cutaneous colonization and undue patient vulnerability.
The application of an attachable silver-impregnated detachable cuff to a short-term CVC or Swan-Ganz introducer at the time of insertion in a new site can significantly reduce the risk of CVC-related bloodstream infection (pooled RR 0.90; 95% CI 0.02–0.81) (48,90), but the device does not appear to confer benefit with second catheters placed over a guidewire in an old site (90). Other studies have failed to show a decline in catheter-related bloodstream infection with the cuff (57,126,167); however, the use of the cuff permitted extended placement of the catheter without increasing the incidence of sepsis (126,167). The silver-impregnated cuff has been supplanted by better and more effective technology for reducing risk of CVC-related bloodstream infection, as described below.
The BioPatch (Ethicon, Somerville, NJ) is a novel chlorhexidine-impregnated hydrophilic polyurethane foam dressing that has been shown to reduce cutaneous colonization under the dressing and colonization of percutaneous epidural catheters (162), and to prevent infection of orthopedic traction pin sites (37). The device can be affixed about a newly inserted CVC, pressed firmly onto the skin about the site, and covered with a transparent polyurethane dressing to suppress cutaneous colonization by microorganisms that might invade the tract and cause CVC-related bloodstream infection.
Three randomized trials have evaluated the efficacy of the chlorhexidine sponge dressing for the prevention of CVC-related infection (51,56,97). Hanazaki et al (56) found significantly reduced rates of cutaneous colonization of the catheter insertion site with the use of the chlorhexidine dressing in a randomized trial; however, no attempt was made to identify catheter colonization or CVC-related bloodstream infection. Garland et al (51) examined the efficacy of the chlorhexidine sponge dressing in a multicenter trial in 6 neonatal intensive care units. The study showed that the novel dressing, replaced weekly, gave results comparable to gauze and tape, with periodic cutaneous disinfection with 10% povidone-iodine, for prevention of cutaneous colonization and catheter-related bloodstream infection. However, use of the chlorhexidine dressing in low-birthweight neonates (<1,000 g) was associated with a 15% incidence of dermatotoxicity.
In the third study, a randomized trial (97) of the device in patients in a university hospital intensive care unit scheduled to receive a percutaneously inserted noncuffed CVC, peripherally inserted CVC (PICC), or arterial catheter for hemodynamic monitoring, use of the chlorhexidine dressing was associated with a substantial reduction in the incidence of CVC-related bloodstream infection (3.3 versus 5.7 bloodstream infection per 1,000 intravascular device [IVD]-days, RR 0.41; 95% CI 0.09–0.83). There was no evidence that the routine use of the device led to reduced susceptibility of colonizing organisms to chlorhexidine. These data suggest that this novel and inexpensive technology warrants consideration for use on arterial catheters and PICCs, and, for centers not using anti-infective catheters, on noncuffed CVCs as well (see Table 5) (128).
Anti-infective catheter coatings:
Adherence of microorganisms to the catheter surface is an integral stage in the pathogenesis of CVC-related bloodstream infection (55,180). Thus, binding a nontoxic antiseptic or antimicrobial to the catheter surface or incorporating an anti-infective agent or agents in the catheter material itself might prove to be the most effective technologic innovation for preventing device-related infection (181).
The greatest benefit of new technology has come from coating the catheter surface with a nontoxic anti-infective agent or incorporating such a substance into the catheter material itself. Critical scrutiny of the risk of catheter-related bloodstream infections with pulmonary artery Swan-Ganz catheters suggests that heparin-bonded catheters, which exhibit surface antimicrobial activity because of the benzalkonium chloride used to bind the heparin to the surface, significantly reduce the risk of catheter-related colonization and bloodstream infection (114,122). Beyond the benefit for reduction of surface thrombosis, these data suggest that except for patients with documented intolerance of heparin, such as heparin-related thrombocytopenia, if a pulmonary artery catheter is to be inserted, the use of a heparin-bonded catheter can reduce the risk of catheter-related bloodstream infection (147).
In a randomized clinical trial (71), central venous and arterial catheters coated with cefazolin at the time of insertion were associated with a sevenfold reduction in catheter colonization and a tenfold reduction in catheter-related bloodstream infection. Triple-lumen polyurethane CVCs coated with 2 antiseptics, silver-sulfadiazine and chlorhexidine, appear to reduce the risk of catheter-related bloodstream infection by approximately 50% (181). Careful analysis of all isolates recovered from colonized and infected catheters in 1 study (100) showed no evidence of emerging resistance to the antiseptic agents.
An even more effective strategy aimed at reducing surface colonization by skin organisms is the use of the novel antibiotic combination, minocycline and rifampin, applied both to the external and inner surface of CVCs at the time of manufacture. Randomized trials of these catheters have shown a 90% reduction in CVC-related bloodstream infection (RR 0.08–0.09) (35,143). Limited studies have not shown resistance; however, relatively few isolates were examined.
These studies show that using CVCs with antiinfective coatings clearly reduces risk and should be strongly considered by centers seeking to reduce their rate of CVC-related bloodstream infection, especially in targeted patients at highest risk. However, the long-term impact of using anti-infective-coated CVCs must be closely monitored to ascertain their ecologic impact on skin organisms that are potential bloodstream pathogens. Whenever topical antibacterials have been used on skin or mucosal surfaces in hospitalized patients, significant resistance has been encountered (15,29,42,62,158,185). The challenge for the future will be developing more potent surface agents that are well tolerated and do not promote resistance.
An antimicrobial- or antiseptic-impregnated CVC should be used in adults whose catheter is expected to remain in place >5 days if, after implementing a comprehensive strategy to reduce rates of catheter-related bloodstream infection, the rate remains above the goal set by the institution based on benchmark rates and local factors. The comprehensive strategy should include the following 3 components: education of persons who insert and maintain catheters, use of maximal sterile barrier precautions, and a 2% chlorhexidine preparation for skin antisepsis during CVC insertion (see Table 5) (128).
Contamination of the catheter hub or lumen
A substantial number of CVC-related bloodstream infections clearly derive from luminal contaminants, particularly organisms that contaminate the hub, where the administration set is attached to the catheter, and which contaminates infusate in the lumen of the catheter. This mechanism of infection is the major cause of catheter-related bloodstream infection with long-term, cuffed Hickman-like CVCs and subcutaneous central ports (23,182), but also becomes important with short-term, noncuffed CVCs that are left in place for prolonged periods, beyond 5–7 days (78,165,166). It is unknown whether routine replacement of the administration set and entire delivery system at periodic intervals, usually 48 hours in the United States, reduces the risk of hub contamination-related bloodstream infections.
Perhaps the greatest promise here is, again, new technology: a novel catheter hub, engineered to reduce the risk of hub contamination, incorporates an antiseptic solution that is pierced by a blunt needle and was shown in a European randomized trial to substantially reduce the risk of CVC-related bloodstream infection (RR 0.2; 95% CI 0.1–0.7) (159). A subsequent, randomized trial of this new hub device in 130 catheters, however, failed to show a protective effect (81). Further studies are needed to better evaluate the role of this novel, potentially promising hub device for the prevention of catheter-related bloodstream infection. Moreover, the use of luminal lock solutions containing an anticoagulant with intrinsic antibacterial activity, such as oxalate or citrate or an anti-infective such as vancomycin, has been shown to greatly reduce the risk of catheter-related bloodstream infection with hemodialysis and other long-term CVCs or central ports (14,22,60,155).
These studies suggest that these technologies for preventing catheter-related bloodstream infections caused by intraluminal contaminants with long-term CVCs, especially hemodialysis catheters and cuffed and tunneled CVCs, ports, and PICCs, should be considered for routine use in centers with high rates of catheter-related bloodstream infection, or in individual patients who appear to be unusually susceptible to infection.
Prolonged catheter placement
Exactly how long noncuffed short-term CVCs can be left in place safely, particularly in critically ill patients in an intensive care unit, has not been adequately assessed. In general, however, most studies that have examined duration of placement as a risk factor have shown that prolonged placement significantly increases the cumulative risk of infection, particularly insertions longer than 5–7 days (3,43,45,52,107,152). The need for continued use of an intravascular catheter should be frequently re-assessed, and the device should be removed as soon as the intended use is over (74).
It has not been conclusively established whether routine replacement of a noncuffed CVC to a new site at periodic intervals, such as every 4–5 days, significantly reduces the risk of CVC-related bloodstream infection in patients requiring prolonged central access. While some studies report no decline in the incidence of CVC-related bloodstream infection with routine replacement (16,20,26,45), most have not had sufficient statistical power to answer the question (11,45,177). This question remains unanswered; however, the availability of novel technology may obviate this concern. The studies of anti-infective-coated CVCs show a sufficiently reduced risk of CVC-related bloodstream infection that, in patients requiring prolonged central access, it appears to be safe to leave a CVC in place for 10–20 days, if necessary, perhaps even longer if the device is dedicated to total parenteral nutrition or anti-infective therapy (127). Moreover, the use of chlorhexidine-impregnated dressings or engineered contamination-resistant catheter hubs can further reduce risk and permit virtually indefinite cannulation with a low risk of infection.
Recent studies have shown that the intensity of nursing care, measured by a nurse-to-patient ratio, has a significant impact on the risk of nosocomial infections among patients in that unit, especially intensive care units (154). In an era where United States hospitals are struggling to recruit nurses and the temptation to ask nurses to care for increasing numbers of critically ill patients, this finding has much importance. Health care systems must recognize the importance of assuring sufficient numbers of nursing staff to provide basic care, especially in intensive care units (50). We believe that wider use of novel technology, such as chlorhexidineimpregnated site dressings or CVCs with anti-infective coatings, holds the greatest promise to prevent CVC-related bloodstream infections in an era of critical nursing shortages, especially in intensive care units (156).
In conclusion, the greatest challenge in reducing the risk of CVC-related bloodstream infection is consistently implementing those control measures shown to be most effective. Recent studies have shown that intensive educational efforts in teaching hospitals, which focus essential control measures, can reduce the risk of vascular catheter-related bloodstream infection (38,130,164). But perhaps the greatest promise has been the evolving novel technology designed for prevention (109,156). Many hospitals have been reluctant to adapt these technologies despite an increasing number of studies affirming their benefit and especially their cost-benefit. Hospitals are strongly encouraged to consider adapting these technologies, which can further reduce the risk of serious CVC-related bloodstream infection, especially in those patients at highest risk of infection.
Better prospective studies of sufficient size to address all potential risk factors, including insertion site colonization, hub and luminal contamination, insertion technique, and follow-up care, would enhance our understanding of the pathogenesis of CVC-related bloodstream infection and guide efforts to develop even more effective strategies for prevention.
1. Adal KA, Farr BM. Central venous catheter-related infections: A review. Nutrition 12: 208–13, 1996.
2. Almirall J, Gonzalez J, Rello J, Campistol JM, Montoliu J, Puig de la Bellacasa J, Revert L, Gatell JM. Infection of hemodialysis catheters: Incidence and mechanisms. Am J Nephrol 9: 454–9, 1989.
3. Alonso-Echanove J, Edwards J, Richards M, Gaynes RP. Risk factors for central line-associated bloodstream infections: Preliminary analysis of the detailed intensive care unit surveillance component study [Abstract]. In: Programs and abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, March 5–9, Atlanta, GA. Infect Control Hosp Epidemiol 21: 86–174, 2000.
4. Andersen PT, Herlevsen P, Schaumburg H. A comparative study of “op-site” and “nobecutan gauze” dressings for central venous line care. J Hosp Infect 7: 161–8, 1986.
5. Andrivet P, Bacquer A, Ngoc CV, Ferme C, Letinier JY, Gautier H, Gallet CB, Brun-Buisson C. Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. Clin Infect Dis 18: 199–206, 1994.
6. Anonymous. Information for applicants. Philadelphia: The American Board of Internal Medicine, pp 1–6, 2000.
7. Armstrong CW, Mayhall CG, Miller KB, Newsome Jr, HH Sugerman HJ, Dalton HP, Hall GO, Gennings C. Prospective study of catheter replacement and other risk factors for infection of hyperalimentation catheters. J Infect Dis 154: 808–16, 1986.
8. Armstrong CW, Mayhall CG, Miller KB, Newsome Jr, HH Sugerman HJ, Dalton HP, Hall GO, Hunsberger S. Clinical predictors of infection of central venous catheters used for total parenteral nutrition. Infect Control Hosp Epidemiol 11: 71–8, 1990.
9. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 16: 778–84, 1993.
10. Babycos CR, Barrocas A, Webb WR. A prospective randomized trial comparing the silver-impregnated collagen cuff with the bedside tunneled subclavian catheter. JPEN J Parenter Enteral Nutr 17: 61–3, 1993.
11. Bach A, Bohrer H, Geiss HK. Safety of a guidewire technique for replacement of pulmonary artery catheters. J Cardiothorac Vasc Anesth 6: 711–4, 1992.
12. Badley AD, Steckelberg JM, Wollan PC, Thompson RL. Infectious rates of central venous pressure catheters: Comparison between newly placed catheters and those that have been changed. Mayo Clin Proc 71: 838–46, 1996.
13. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Surveillance System. Am J Med 91( 3B): 86S–89S, 1991.
14. Barriga FJ, Varas M, Potin M, Sapunar F, Rojo H, Martinez A, Capdeville V, Becker A, Vial PA. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 28: 196–200, 1997.
15. Bastos MC, Mondino PJ, Azevedo ML, Santos KR, Giambiagi-deMarval M. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur J Clin Microbiol Infect Dis 18: 393–8, 1999.
16. Berthelot P, Zeni F, Pain P, Berthier S, Aubert G, Venet C, Gery P, Lucht F, Bertrand JC. Catheter infection in intensive care: Influence of systematic replacement of central venous catheters on a guide wire every 4 days. Presse Med 26: 1089–94, 1997.
17. Blake PG, Huraib S, Wu G, Uldall PR. The use of dual lumen jugular venous catheters as definitive long term access for haemodialysis. Int J Artif Organs 13: 26–31, 1990.
18. Blot F, Chachaty E, Raynard B, Antoun S, Bourgain JL, Nitenberg G. Mechanisms and risk factors for infection of pulmonary artery catheters and introducer sheaths in cancer patients admitted to an intensive care unit. J Hosp Infect 48: 289–97, 2001.
19. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, Callender DPE, Yang JC, Lotze MT, Pizzo PA, Rosenberg SA. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8: 161–9, 1990.
20. Bregenzer T, Conen D, Sakmann P, Widmer AF. Is routine replacement of peripheral intravenous catheters necessary? Arch Intern Med 158: 151–6, 1998.
21. Canaud B, Beraud JJ, Joyeux H, Mion C. Internal jugular vein cannulation using 2 silastic catheters. Nephron 43: 133–8, 1986.
22. Carratala J, Niubo J, Fernandez-Sevilla A, Juve E, Castellsague X, Berlanga J, Linares J, Gudiol F. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 43: 2200–4, 1999.
23. Cheesbrough JS, Finch RG, Burden RP. A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 154: 579–89, 1986.
24. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg 62: 641–6, 1996.
25. Clark-Christoff N, Watters VA, Sparks W, Snyder P, Grant JP. Use of triple-lumen subclavian catheters for administration of total parenteral nutrition. JPEN J Parenter Enteral Nutr 16: 403–7, 1992.
26. Cobb DK, High KP, Sawyer RG, Sable CA, Adams RB, Lindley DA, Pruett TL, Schwenzer KJ, Farr BM. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med 327: 1062–8, 1992.
27. Conly JM, Grieves K, Peters B. A prospective, randomized study comparing transparent and dry gauze dressings for central venous catheters. J Infect Dis 159: 310–9, 1989.
28. Cook D, Randolph A, Kernerman P, Cupido C, King D, Soukup C, Brun-Buisson C. Central venous catheter replacement strategies: A systematic review of the literature. Crit Care Med 25: 1417–24, 1997.
29. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41: 11–8, 1998.
30. Cookson BD, Lacey RW, Noble WC, Reeves DS, Wise R, Redhead RJ. Mupirocin-resistant Staphylococcus aureus. Lancet 335: 1095–6, 1990.
31. Cunha BA. Diagnosis and prevention of intravenous central line-associated infections. Heart Lung 24: 261–2, 1995.
32. Dahlberg PJ, Agger WA, Singer JR, Yutuc WR, Newcomer KL, Schaper A, Rooney BL. Subclavian hemodialysis catheter infections: A prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections. Infect Control Hosp Epidemiol 16: 506–11, 1995.
33. Damen J. The microbiologic risk of invasive haemodynamic monitoring in open-heart patients requiring prolonged ICU treatment. Intensive Care Med 14: 156–62, 1988.
34. Damen J, Verhoef J, Bolton DT, Middleton NG, van der Tweel I, de Jonge K, Wever JE, Nijsen-Karelse M. Microbiologic risk of invasive hemodynamic monitoring in patients undergoing open-heart operations. Crit Care Med 13: 548–55, 1985.
35. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, Berg J, Khardori N, Hanna H, Hachem R, Harris RL, Mayhall G. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 340: 1–8, 1999.
36. Deitel M, Krajden S, Saldanha CF, Gregory WD, Fuksa M, Cantwell E. An outbreak of Staphylococcus epidermidis septicemia. JPEN J Parenter Enteral Nutr 7: 569–72, 1983.
37. DeJong ME, DeBerardino MT, Brooks DE, Nelson MB, Campbell AA, Bottoni MC, Pusateri AE, Walton MR, Guymon CH, McManus AT. Antimicrobial efficacy of external fixator pins coated with a lipid stabilized hydroxyapatite/chlorhexidine complex to prevent pin tract infection in a goat model. J Trauma 50: 1008–14, 2001.
38. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 355: 1864–8, 2000.
39. Ehrenkranz NJ, Eckert DG, Phillips PM. Sporadic bacteremia complicating central venous catheter use in a community hospital: A model to predict frequency and aid in decision-making for initiation of investigation. Am J Infect Control 17: 69–76, 1989.
40. Elliott TSJ, Farouqi MH, Armstrong RF, Hanson GC. Guidelines for good practice in central venous catheterization. J Hosp Infect 28: 163–76, 1994.
41. Elliott TSJ, Tebbs SE. Prevention of central venous catheter-related infection. J Hosp Infect 40: 193–201, 1998.
42. Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 35: 1–8, 1997.
43. Ena J, Cercenado E, Martinez D, Bouza E. Cross-sectional epidemiology of phlebitis and catheter-related infections. Infect Control Hosp Epidemiol 13: 15–20, 1992.
44. Engervall P, Ringertz S, Hagman E, Skogman K, Bjorkholm M. Change of central venous catheter dressings twice a week is superior to once a week in patients with haematological malignancies. J Hosp Infect 29: 275–86, 1995.
45. Eyer S, Brummitt C, Crossley K, Siegel R, Cerra F. Catheter-related sepsis: Prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med 18: 1073–9, 1990.
46. Farkas JC, Liu N, Bleriot JP, Chevret S, Goldstein FW, Carlet J. Single-versus triple-lumen central catheter-related sepsis: A prospective randomized study in a critically ill population. Am J Med 93: 277–82, 1992.
47. Farr BM. Preventing vascular catheter-related infections: Current controversies. Clin Infect Dis 33: 1733–8, 2001.
48. Flowers RH, Schwenzer KJ, Kopel RF, Fisch MJ, Tucker SI, Farr BM. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection. A randomized, controlled trial. JAMA 261: 878–83, 1989.
49. Franceschi D, Gerding RL, Phillips G, Fratianne RB. Risk factors associated with intravascular catheter infections in burned patients: A prospective, randomized study. J Trauma 29: 811–6, 1989.
50. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR. The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol 17: 150–8, 1996.
51. Garland JS, Alex CP, Mueller CD, Otten D, Shivpuri C, Harris MC, Naples M, Pellegrini J, Buck RK, McAuliffe TL, Goldmann DA, Maki DG. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics 107: 1431–6, 2001.
52. Gil RT, Kruse JA, Thill-Baharozian MC, Carlson RW. Triple-vs single-lumen central venous catheters. A prospective study in a critically ill population. Arch Intern Med 149: 1139–43, 1989.
53. Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheters: Effect of site of placement and catheter type. Infect Control Hosp Epidemiol 19: 842–5, 1998.
54. Greene JN. Catheter-related complications of cancer therapy. Infect Dis Clin North Am 10: 255–94, 1996.
55. Gristina AG. Biomaterial-centered infection: Microbial adhesion versus tissue integration. Science 237: 1588–95, 1987.
56. Hanazaki K, Shingu K, Adachi W, Miyazaki T, Amano J. Chlorhexidine dressing for reduction in microbial colonization of the skin with central venous catheters: A prospective randomized controlled trial. J Hosp Infect 42: 165–8, 1999.
57. Hasaniya NW, Angelis M, Brown MR, Yu M. Efficacy of subcutaneous silver-impregnated cuffs in preventing central venous catheter infections. Chest 109: 1030–2, 1996.
58. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, Edwards LP, O’Connell FM, Puyana JC, Doern GV. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 158: 81–7, 1998.
59. Heiselman D. Nosocomial bloodstream infection in the critically ill. JAMA 272: 1819–20, 1994.
60. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, Klein JP. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. J Clin Oncol 18: 1269–78, 2000.
61. High KP, Cobb DK, Sable CA. A randomized controlled trial of scheduled central venous catheter (CVC) replacement. In: Programs and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990.
62. Hill RL, Casewell MW. Reduction in the colonization of central venous cannulae by mupirocin. J Hosp Infect 19(Suppl B): 47–57, 1991.
63. Hill RL, Fisher AP, Ware RJ, Wilson S, Casewell MW. Mupirocin for the reduction of colonization of internal jugular cannulae—a randomized controlled trial. J Hosp Infect 15: 311–21, 1990.
64. Hilton E, Haslett TM, Borenstein MT, Tucci V, Isenberg HD, Singer C. Central catheter infections: Single-versus triple-lumen catheters. Influence of guide wires on infection rates when used for replacement of catheters. Am J Med 84: 667–72, 1988.
65. Hoffmann KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. JAMA 267: 2072–6, 1992.
66. Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunnelled central venous catheters. Cancer 75: 1367–75, 1995.
67. Humar A, Ostromecki A, Direnfeld J, Marshall JC, Lazar N, Houston PC, Boiteau P, Conly JM. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. Clin Infect Dis 31: 1001–7, 2000.
68. Iberti TJ, Fischer EP, Leibowitz AB, Panacek EA, Silverstein JH, Albertson TE, Group atPaCS. A multicenter study of physicians’ knowledge of the pulmonary artery catheter. JAMA 264: 2928–32, 1990.
69. Inoue Y, Nezu R, Matsuda H, Fujii M, Nakai S, Wasa M, Takagi Y, Okada A. Prevention of catheter-related sepsis during parenteral nutrition: Effect of a new connection device. JPEN J Parenter Enteral Nutr 16: 581–5, 1992.
70. Jarvis WR. Nosocomial outbreaks: The Centers for Disease Control’s Hospital Infections Program experience, 1980–1990. Epidemiology Branch, Hospital Infections Program. Am J Med 91: 101S–106S, 1991.
71. Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA 265: 2364–8, 1991.
72. Kealey GP, Chang P, Heinle J, Rosenquist MD, Lewis II. RW Prospective comparison of two management strategies of central venous catheters in burn patients. J Trauma 38: 344–9, 1995.
72a. Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters [Abstract]. Infect Control Hosp Epidemiol 21: 96, 2000.
73. Lacey RW. Antibacterial action of human skin. In vivo effect of acetone, alcohol and soap on behaviour of Staphylococcus aureus. Br J Exp Pathol 49: 209–15, 1968.
74. Lederle FA, Parenti CM, Berskow LC, Ellingson KJ. The idle intravenous catheter. Ann Intern Med 116: 737–8, 1992.
75. Lee RB, Buckner M, Sharp KW. Do multi-lumen catheters increase central venous catheter sepsis compared to single-lumen catheters. J Trauma 28: 1472–5, 1988.
76. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int 40: 934–8, 1991.
77. Linares J, Dominguez MA, Martin R. Current laboratory techniques in the diagnosis of catheter-related infections. Nutrition 13(Suppl): 10S–14S, 1997.
78. Linares J, Sitges-Serra A, Garau J, Perez JL, Martin R. Pathogenesis of catheter sepsis: A prospective study with quantitative and semiquantitative cultures of catheter hub and segments. J Clin Microbiol 21: 357–60, 1985.
79. Logghe C, Van Ossel C, D’Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: A randomized controlled trial. J Hosp Infect 37: 145–56, 1997.
80. Loo S, van Heerden PV, Gollege CL, Roberts BL, Power BM. Infection in central lines: Antiseptic-impregnated vs standard non-impregnated catheters. Anaesth Intensive Care 25: 637–9, 1997.
81. Luna J, Masdeu G, Perez M, Claramonte R, Forcadell I, Barrachina F, Panisello M. Clinical trial evaluating a new hub device designed to prevent catheter-related sepsis. Eur J Clin Microbiol Infect Dis 19: 655–62, 2000.
82. Mackel DC, Maki DG, Anderson RL, Rhame FS, Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products: Mechanisms of intrinsic contamination. J Clin Microbiol 2: 486–97, 1975.
83. Madeo M, Martin CR, Turner C, Kirkby V, Thompson DR. A randomized trial comparing Arglaes (a transparent dressing containing silver ions) to Tegaderm (a transparent polyurethane dressing) for dressing peripheral arterial catheters and central vascular catheters. Intensive Crit Care Nurs 14: 187–91, 1998.
84. Mahieu LM, De Dooy JJ, Lenaerts AE, Ieven MM, De Muynck AO. Catheter manipulations and the risk of catheter-associated bloodstream infection in neonatal intensive care unit patients. J Hosp Infect 48: 20–6, 2001.
85. Mahieu LM, De Muynck AO, Ieven MM, De Dooy JJ, Goossens HJ, Van Reempts PJ. Risk factors for central vascular catheter-associated bloodstream infections among patients in a neonatal intensive care unit. J Hosp Infect 48: 108–16, 2001.
86. Maki DG. Marked differences in skin colonization of insertion sites for central venous, arterial, and peripheral IV catheters: The major reason for differing risks of catheter-related infection? In: Programs and Abstracts of the 3rd International Conference on Nosocomial Infections, Atlanta, GA, 1990.
87. Maki DG. Nosocomial bacteremia. Am J Med 70: 183–96, 1981.
88. Maki DG. Pathogenesis, prevention and management of infections due to intravascular devices used for infusion therapy. In: Bison AL, Waldvogel F, eds. Infections associated with indwelling medical devices. Washington, DC: American Society for Microbiology, pp 161–77, 1989.
89. Maki DG, Band JD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am J Med 70: 739–44, 1981.
90. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: A prospective randomized multicenter trial. Am J Med 85: 307–14, 1988.
91. Maki DG, Goldmann DA, Rhame FS. Infection control in intravenous therapy. Ann Intern Med 79: 867–87, 1973.
92. Maki DG, Knasinski V, Narans L, Gordon BJ. A randomized trial of a novel 1% chlorhexidine-75% alcohol tincture versus 10% povidoneiodine for cutaneous disinfection with vascular catheters. In: 31st Annual Society for Healthcare Epidemiology of America Meeting, Toronto, Canada, 2001.
93. Maki DG, McCormack KN. Defatting catheter insertion sites in total parenteral nutrition is of no value as an infection control measure. Controlled clinical trial. Am J Med 83: 833–40, 1987.
94. Maki DG, Mermel LA. Infections due to infusion therapy. In: Bennet JV, Brachman PS, eds. Hospital infections. Philadelphia: Lippincott-Raven, pp 689–724, 1998.
95. Maki DG, Mermel LA. Meta-analysis of transparent vs gauze dressing for central venous catheter use [Abstract]. Infect Control Hosp Epidemiol 18(Suppl 2): 51, 1997.
96. Maki DG, Mermel LA, Martin M, Knasinski V, Berry D. A highly semipermeable polyurethane dressing does not increase the risk of CVCrelated BSI: A prospective, multicenter, investigator blinded trial. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
97. Maki DG, Narans L, Knasinski V, Kluger DM. Prospective randomised, investigator-masked trial of a novel chlorhexidine-impregnated disk (Biopatch) on central venous and arterial catheters. In: Proceedings and Abstracts of the 4th International Decennial Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, GA, 2000.
98. Maki DG, Rhame FS, Mackel DC, Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products. I. Epidemiologic and clinical features. Am J Med 60: 471–85, 1976.
99. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338: 339–43, 1991.
100. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antisepticimpregnated catheter. A randomized, controlled trial. Ann Intern Med 127: 257–66, 1997.
101. Maki DG, Stolz SM, Wheeler S, Mermel LA. A prospective, randomised trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: Implications for catheter management. Crit Care Med 22: 1729–37, 1994.
102. Maki DG, Will L. Colonization and infection associated with transparent dressing for central venous, arterial and Hickman catheters: A comparative study. In: Programs and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1984.
103. Maki DG, Will L. Risk factors for central venous catheter-related infections within the ICU: A prospective study of 345 catheters. In: Programs and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990.
104. Maki DG, Will L. Study of polyantibiotic and povidone-iodine ointments on central venous and arterial catheter sites dressed with gauze or polyurethane dressing. In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1986.
105. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 127: 275–80, 1997.
106. Martin C, Bruder N, Papazian L, Saux P, Gouin F. Catheter-related infections following axillary vein catheterization. Acta Anaesthesiol Scand 42: 52–6, 1998.
107. McCarthy MC, Shives JK, Robison RJ, Broadie TA. Prospective evaluation of single and triple lumen catheters in total parenteral nutrition. JPEN J Parenter Enteral Nutr 11: 259–62, 1987.
108. Meffre C, Girard R, Hajjar J, Fabry J. Povidone-iodine vs alcoholic chlorhexidine for disinfection of the insertion site of peripheral intravenous catheters: Results of a multicenter randomized trial. In: Programs and Abstracts of the 26th Annual Society for Healthcare Epidemiology of America Meeting, 1996.
109. Mermel LA. New technologies to prevent intravascular catheterrelated bloodstream infections. Emerg Infect Dis 7: 197–9, 2001.
110. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 132: 391–401, 2000.
111. Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs 24: 180–205, 2001.
112. Mermel LA, Maki DG. Infectious complications of Swan-Ganz pulmonary artery catheters: Pathogenesis, epidemiology, prevention and management. Am J Respir Crit Care Med 149: 1020–36, 1994.
113. Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: A prospective study utilizing molecular subtyping. Am J Med 91(Suppl 3B): 1897–205, 1991.
114. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis 167: 920–4, 1993.
115. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, Rigaud JP, Casciani D, Misset B, Bosquet C, Outin H, Brun-Buisson C, Nitenberg G. Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA 286: 700–7, 2001.
116. Michalopoulos A, Geroulanos S. Central venous catheter-related infections. Eur J Anaesthesiol 13: 445–55, 1996.
117. Michel LA, Bradpiece HA, Randour P, Pouthier F. Safety of central venous catheter change over guidewire for suspected catheter-related sepsis. A prospective randomized trial. Int Surg 73: 180–6, 1988.
118. Miller JA, Singireddy S, Maldjian P, Baker SR. A reevaluation of the radiographically detectable complications of percutaneous venous access lines inserted by four subcutaneous approaches. Am Surg 65: 125–30, 1999.
119. Miller JM, Goetz AM, Squier C, Muder RR. Reduction in nosocomial intravenous device-related bacteremias after institution of an intravenous therapy team. J Intraven Nurs 19: 103–6, 1996.
120. Mimoz O, Pieroni L, Lawrence C, Edouard A, Costa Y, Samii K, Brun-Buisson C. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med 24: 1818–23, 1996.
121. Moro ML, Vigano EF, Cozzi Lepri A. Risk factors for central venous catheter-related infections in surgical and intensive care units. The Central Venous Catheter-Related Infections Study Group. Infect Control Hosp Epidemiol 15: 253–64, 1994.
122. Moss HA, Tebbs SE, Faroqui MH, Herbst T, Isaac JL, Brown J, Elliott TS. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur J Anaesthesiol 17: 680–7, 2000.
123. Myers ML, Austin TW, Sibbald WJ. Pulmonary artery catheter infections: A prospective study. Ann Surg 201: 237–41, 1985.
124. Newman KA, Reed WP, Schimpff SC, Bustamante CI, Wade JC. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer 1: 92–7, 1993.
125. Nikoletti S, Leslie G, Gandossi S, Coombs G, Wilson R. A prospective, randomized, controlled trial comparing transparent polyurethane and hydrocolloid dressings for central venous catheters. Am J Infect Control 27: 488–96, 1999.
126. Norwood S, Hajjar G, Jenkins L. The influence of an attachable subcutaneous cuff for preventing triple lumen catheter infections in critically ill surgical and trauma patients. Surg Gynecol Obstet 175: 33–40, 1992.
127. Norwood S, Wilkins III, HE Vallina VL, Fernandez LG, McLarty JW. The safety of prolonging the use of central venous catheters: A prospective analysis of the effects of using antiseptic-bonded catheters with daily site care. Crit Care Med 28: 1376–82, 2000.
128. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA. Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep 51( RR-10): 1–29, 2002.
129. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int 58: 2543–5, 2000.
130. Parenti CM, Lederle FA, Impola CL, Peterson LR. Reduction of unnecessary intravenous catheter use. Internal medicine house staff participate in a successful quality improvement project. Arch Intern Med 154: 1829–32, 1994.
131. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 17: 438–73, 1996.
132. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters. A prospective randomized trial. Arch Surg 131: 986–9, 1996.
133. Pettigrew RA, Lang SDR, Haydock DA, Parry BR, Bremner DA, Hill GL. Catheter-related sepsis in patients on intravenous nutrition: A prospective study of quantitative catheter cultures and guidewire changes for suspected sepsis. Br J Surg 72: 52–55, 1985.
134. Pittet D. Intravenous catheter-related infections: Current understanding. In: Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
135. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs and attributable mortality. JAMA 271: 1598–601, 1994.
136. Polderman KH, Girbes AJ. Central venous catheter use. Part 1: Mechanical complications. Intensive Care Med 28: 1–17, 2002.
137. Powell C, Fabri PJ, Kudsk KA. Risk of infection accompanying the use of single-lumen vs double-lumen subclavian catheters: A prospective randomised study. JPEN J Parenter Enteral Nutr 12: 127–9, 1988.
138. Powell C, Regan C, Fabri PJ, Ruberg RL. Evaluation of opsite catheter dressings for parenteral nutrition: A prospective, randomized study. JPEN J Parenter Enteral Nutr 6: 43–6, 1982.
139. Powell CR, Traetow MJ, Fabri PJ, Kudsk KA, Ruberg RL. Op-site dressing study: A prospective, randomized study evaluating povidone-iodine ointment and extension set changes with 7-day op-site dressings applied to total parenteral nutrition subclavian sites. JPEN J Parenter Enteral Nutr 9: 443–6, 1985.
140. Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA, Marts K, Mansfield PF, Bodey GP. Prevention of central venous catheterrelated infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 15: 231–8, 1994.
141. Raad I. Intravascular catheter-related infections. Lancet 351: 893–8, 1998.
142. Raad I, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 15: 197–208, 1992.
143. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 127: 267–74, 1997.
144. Raad I, Darouiche RO. Catheter-related septicemia: Risk reduction. Infections in Medicine 13: 807–23, 1996.
145. Rahman M, Connolly S, Noble WC, Cookson B, Phillips I. Diversity of staphylococci exhibiting high-level resistance to mupirocin. J Med Microbiol 33: 97–100, 1990.
146. Rahman M, Noble WC, Cookson B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect 102: 261–70, 1989.
147. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: A meta-analysis of randomized controlled trials. Chest 113: 165–71, 1998.
148. Randolph AG, Cook DJ, Gonzales CA, Brun-Buisson C. Tunneling short-term central venous catheters to prevent catheter-related infection: A meta-analysis of randomized, controlled trials. Crit Care Med 26: 1452–7, 1998.
149. Rao SP, Oreopoulos DG. Unusual complications of a polyurethane PD catheter. Perit Dial Int 17: 410–2, 1997.
150. Rello J, Coll P, Net A, Prats G. Infection of pulmonary artery catheters. Epidemiologic characteristics and multivariate analysis of risk factors. Chest 103: 132–6, 1993.
151. Reynolds MG, Tebbs SE, Elliott TS. Do dressings with increased permeability reduce the incidence of central venous catheter related sepsis? Intensive Crit Care Nurs 13: 26–9, 1997.
152. Richet H, Hubert B, Nitemberg G, Andremont A, Buu-Hoi A, Ourbak P, Galicier C, Veron M, Boisivon A, Bouvier AM, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol 28: 2520–5, 1990.
153. Riu S, Ruiz CG, Martinez-Vea A, Peralta C, Oliver JA. Spontaneous rupture of polyurethane peritoneal catheter. A possible deleterious effect of mupirocin ointment. Nephrol Dial Transplant 13: 1870–1, 1998.
154. Robert J, Fridkin SK, Blumberg HM, Anderson B, White N, Ray SM, Chan J, Jarvis WR. The influence of the composition of the nursing staff on primary bloodstream infection rates in a surgical intensive care unit. Infect Control Hosp Epidemiol 21: 12–7, 2000.
155. Rubie H, Juricic M, Claeyssens S, Krimou A, Lemozy J, Izard P, Guitard J, Ane M, Prere MF, Fedacou F, et al. Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer. Arch Dis Child 72: 325–9, 1995.
156. Safdar N, Crnich CJ, Maki DG. Nosocomial infections in the intensive care unit associated with invasive medical devices. Curr Infect Dis Rep 3: 487–95, 2001.
157. Savage AP, Picard M, Hopkins CC, Malt RA. Complications and survival of multilumen central venous catheters used for total parenteral nutrition. Br J Surg 80: 1287–90, 1993.
158. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, Jones ME. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 42: 489–95, 1998.
159. Segura M, Alvarez-Lerma F, Tellado JM, Jimenez-Ferreres J, Oms L, Rello J, Baro T, Sanchez R, Morera A, Mariscal D, Marrugat J, Sitges-Serra A. A clinical trial on the prevention of catheter-related sepsis using a new hub model. Ann Surg 223: 363–9, 1996.
160. Senagore A, Waller JD, Bonnell BW, Bursch LR, Scholten DJ. Pulmonary artery catheterization: A prospective study of internal jugular and subclavian approaches. Crit Care Med 15: 35–7, 1987.
161. Sesso R, Barbosa D, Leme IL, Sader H, Canziani ME, Manfredi S, Draibe S, Pignatari AC. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: Effect of mupirocin ointment. J Am Soc Nephrol 9: 1085–92, 1998.
162. Shapiro JM, Bond EL, Garman JK. Use of a chlorhexidine dressing to reduce microbial colonization of epidural catheters. Anesthesiology 73: 625–31, 1990.
163. Sheehan G, Leicht K, O’Brien M, Taylor G, Rennie R. Chlorhexidine versus povidone-iodine as cutaneous antisepsis for prevention of vascular catheter-related infection [Abstract]. In: Programs and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993.
164. Sherertz RJ, Ely EW, Westbrook DM, Gledhill KS, Streed SA, Kiger B, Flynn L, Hayes S, Strong S, Cruz J, Bowton DL, Hulgan T, Haponik EF. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 132: 641–8, 2000.
165. Sitges-Serra A, Linares J, Garau J. Catheter sepsis: The clue is the hub. Surgery 97: 355–7, 1985.
166. Sitges-Serra A, Puig P, Linares J, Perez JL, Farrero N, Jaurrieta E, Garau J. Hub colonization as the initial step in an outbreak of catheterrelated sepsis due to coagulase negative staphylococci during parenteral nutrition. JPEN J Parenter Enteral Nutr 8: 668–72, 1984.
167. Smith HO, DeVictoria CL, Garfinkel D, Anderson P, Goldberg GL, Soeiro R, Elia G, Runowicz CD. A prospective randomized comparison of an attached silver-impregnated cuff to prevent central venous catheter-associated infection. Gynecol Oncol 58: 92–100, 1995.
168. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 100: 164–7, 1991.
169. Snyder RH, Archer FJ, Endy T, Allen TW, Condon B, Kaiser J, Whatmore D, Harrington G, McDermott CJ. Catheter infection. A comparison of two catheter maintenance techniques. Ann Surg 208: 651–3, 1988.
170. Still JM, Law E, Thiruvaiyaru D, Belcher K, Donker K. Central linerelated sepsis in acute burn patients. Am Surg 64: 165–70, 1998.
171. Tacconelli E, Tumbarello M, de Gaetano Donati K, Bertagnolio S, Pittiruti M, Leone F, Morace G, Cauda R. Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. J Hosp Infect 44: 186–92, 2000.
172. Tacconelli E, Tumbarello M, Pittiruti M, Leone F, Lucia MB, Cauda R, Ortona L. Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. Eur J Clin Microbiol Infect Dis 16: 203–9, 1997.
173. Tennenberg S, Lieser M, McCurdy B, Boomer G, Howington E, Newman C, Wolf I. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 132: 1348–51, 1997.
174. Timsit JF, Bruneel F, Cheval C, Mamzer MF, Garrouste-Orgeas M, Wolff M, Misset B, Chevret S, Regnier B, Carlet J. Use of tunneled femoral catheters to prevent catheter-related infection. A randomized, controlled trial. Ann Intern Med 130: 729–35, 1999.
175. Timsit JF, Sebille V, Farkas JC, Misset B, Martin JB, Chevret S, Carlet J. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: A prospective randomized multicenter study. JAMA 276: 1416–20, 1996.
176. Trerotola SO, Johnson MS, Shah H, Kraus MA, McKusky MA, Ambrosius WT, Harris VJ, Snidow JJ. Tunneled hemodialysis catheters: Use of a silver-coated catheter for prevention of infection—a randomized study. Radiology 207: 491–6, 1998.
177. Uldall PR, Merchant N, Woods F, Yarworski U, Vas S. Changing subclavian haemodialysis cannulas to reduce infection. Lancet 1: 1373, 1981.
178. van Heerden PV, Webb SA, Fong S, Golledge CL, Roberts BL, Thompson WR. Central venous catheters revisited—infection rates and an assessment of the new Fibrin Analysing System brush. Anaesth Intensive Care 24: 330–3, 1996.
179. Vassilomanolakis M, Plataniotis G, Koumakis G, Hajichristou H, Skouteri H, Dova H, Efremidis AP. Central venous catheter-related infections after bone marrow transplantation in patients with malignancies: A prospective study with short-course vancomycin prophylaxis. Bone Marrow Transplant 15: 77–80, 1995.
180. Vaudaux P, Pittet D, Haeberli A, Huggler E, Nydegger UE, Lew DP, Waldvogel FA. Host factors selectively increase staphylococcal adherence on inserted catheters: A role for fibronectin and fibrinogen or fibrin. J Infect Dis 160: 865–75, 1989.
181. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis. JAMA 281: 261–7, 1999.
182. Weightman NC, Simpson EM, Speller DC, Mott MG, Oakhill A. Bacteraemia related to indwelling central venous catheters: Prevention, diagnosis and treatment. Eur J Clin Microbiol Infect Dis 7: 125–9, 1988.
183. Yeung C, May J, Hughes R. Infection rate for single lumen vs triple lumen subclavian catheters. Infect Control Hosp Epidemiol 9: 154–8, 1988.
184. Young GP, Alexeyeff M, Russell DM, Thomas RJS. Catheter sepsis during parenteral nutrition. JPEN J Parenter Enteral Nutr 12: 365–70, 1988.
185. Zakrzewska-Bode A, Muytjens HL, Liem KD, Hoogkamp-Korstanje JA. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J Hosp Infect 31: 189–93, 1995.
STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Required by 39 U.S.C. 3685)
- Title of publication: MEDICINE.
- Publication no.: 0025-7974.
- Date of filing: 10-01-02.
- Frequency of issue: Bimonthly.
- No. of issues published annually: 6.
- Annual subscription price: $176.00
- Complete mailing address of known office of publication: Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116.
- Complete mailing address of the headquarters or general business offices of the publisher: Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106.
- Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106. Editor: Victor McKusick, The Johns Hopkins Hospital, Institute of Genetic Medicine, Blalock 1007, Baltimore, MD 21287. Managing Editor: Susan Shock, The Johns Hopkins Hospital, Blalock 1007, Baltimore, MD 21287.
- Owner: Lippincott, Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106. 351 West Camden Street, Baltimore, MD 21201, Wolters Kluwer, US, 345 Hudson Street, New York, NY 10014. Wolters Kluwer nv (owns 100% of stock), Stadouderskade 1, 1054 FS Amsterdam, The Netherlands.
- Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
- Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
- Publication Name: MEDICINE.
- Issue Date for circulation data: Volume 81, Number 4.
- Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total no. copies (Net Press Run), 2,700. b) Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on Form 3541 (include advertiser’s proof and exchange copies), 1,084 (2) Paid in-county subscriptions (include advertiser’s proof and exchange copies), none. (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 720. c) Total paid and/or requested circulation (sum of 15b(1), (2), (3), (4), 1,804. d) Free distribution by mail (samples, complimentary, and other free copies): (1) Outside-county as stated on Form 3541, 86. (2) In-county as stated on Form 3541, none. (3) Other classes mailed through the USPS, none. e) Free distribution outside the mail (carriers or other means), 35. (f) Total free distribution (sum of 15d and 15e), 121. g) Total distribution (Sum of 15c and 15f), 1,925. h) Copies not distributed: 775. i) Total (sum of 15g and h, 2,700. j) Percent paid and/or requested circulation: (15c divided by 15g times 100), 94%. Actual no. copies of single issue published nearest to filing date: a) Total no. copies (Net Press Run), 2,700 b) Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on Form 3541 (include advertiser’s proof and exchange copies), 1,742. (2) Paid in-county subscriptions (include advertiser’s proof and exchange copies), none. (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 772. (4) Other classes mailed through the USPS, none. c) Total paid and/or requested circulation (sum of 15b(1),(2), (3), and (4), 2,514. d) Free distribution by mail (samples, complimentary, and other free copies): (1) Outside-county as stated on Form 3541, 41. (2) In-county as stated on Form 3541, none. (3) Other classes mailed through the USPS, none. e) Free distribution outside the mail (carriers or other means), 109. f) Total free distribution (sum of 15d and 15e), 150. g) Total distribution (Sum of 15c and 15f), 2,664. h) Copies not distributed: 36. i) Total (sum of 15g and h) 2,700. j) Percent paid and/or requested circulation (15c divided by 15g times 100), 94%.
- This Statement of Ownership will be printed in the Volume 81, No. 6 issue of this publication.
- I certify that the statements made by me above are correct and complete.
Jeff Brown, Manager